The new drug HM15211, a non-alcoholic fatty hepatitis drug, was fda-designated as a fast-track.
-
Last Update: 2020-07-27
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
!----, Hanmi Pharmaceuticals, said its HM15211 treatment for non-alcoholic fatty hepatitis was given a fast track designation by the FDApicture source: HM15211 has a variety of pharmacological activities that stimulate glucagon-like peptide-1, glucagon and sugar-dependent insulin-releasing peptide (GIP) receptors, reducing excessive accumulation of liver bile acid and inhibiting liver inflammation and fibrosisreported that the company believes that if HM15211 is successfully developed, it could lead to trillions of won worth of non-alcoholic fatty hepatitis drugsHM15211 has previously been awarded the orphan drug title by the U.SDrug Administrationthe pipeline is currently undergoing global Phase II pilot development.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.